Minami Y - Search Results

1

Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies.

Minami Y, Minami H, Miyamoto T, Yoshimoto G, Kobayashi Y, Munakata W, Onishi Y, Kobayashi M, Ikuta M, Chan G, Woolfson A, Ono C, Shaik MN, Fujii Y, Zheng X, Naoe T. Minami Y, et al. Among authors: minami h. Cancer Sci. 2017 Aug;108(8):1628-1633. doi: 10.1111/cas.13285. Epub 2017 Jun 19. Cancer Sci. 2017. PMID: 28556364 Free PMC article. Clinical Trial.

2

Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis.

Kitamura K, Minami Y, Yamamoto K, Akao Y, Kiyoi H, Saito H, Naoe T. Kitamura K, et al. Among authors: minami y. Leukemia. 2000 Oct;14(10):1743-50. doi: 10.1038/sj.leu.2401900. Leukemia. 2000. PMID: 11021749

3

FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy.

Naoe T, Kiyoe H, Yamamoto Y, Minami Y, Yamamoto K, Ueda R, Saito H. Naoe T, et al. Among authors: minami y. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S27-30. doi: 10.1007/s002800100301. Cancer Chemother Pharmacol. 2001. PMID: 11587362 Review.

4

Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors.

Minami Y, Kiyoi H, Yamamoto Y, Yamamoto K, Ueda R, Saito H, Naoe T. Minami Y, et al. Leukemia. 2002 Aug;16(8):1535-40. doi: 10.1038/sj.leu.2402558. Leukemia. 2002. PMID: 12145695

5

Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia.

Minami Y, Yamamoto K, Kiyoi H, Ueda R, Saito H, Naoe T. Minami Y, et al. Blood. 2003 Oct 15;102(8):2969-75. doi: 10.1182/blood-2002-12-3813. Epub 2003 Jul 3. Blood. 2003. PMID: 12842996 Free article.

6

Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy.

Abe A, Minami Y, Hayakawa F, Kitamura K, Nomura Y, Murata M, Katsumi A, Kiyoi H, Jamieson CHM, Wang JYJ, Naoe T. Abe A, et al. Among authors: minami y. Int J Hematol. 2008 Dec;88(5):471-475. doi: 10.1007/s12185-008-0221-1. Epub 2008 Nov 29. Int J Hematol. 2008. PMID: 19039626 Free PMC article.

7

[Circumventing resistance to imatinib therapy in chronic myeloid leukemia].

Minami Y, Naoe T. Minami Y, et al. Gan To Kagaku Ryoho. 2009 Apr;36(4):544-7. Gan To Kagaku Ryoho. 2009. PMID: 19381024 Japanese.

8

Irrespective of CD34 expression, lineage-committed cell fraction reconstitutes and re-establishes transformed Philadelphia chromosome-positive leukemia in NOD/SCID/IL-2Rgammac-/- mice.

Tanizaki R, Nomura Y, Miyata Y, Minami Y, Abe A, Hanamura A, Sawa M, Murata M, Kiyoi H, Matsushita T, Naoe T. Tanizaki R, et al. Among authors: minami y. Cancer Sci. 2010 Mar;101(3):631-8. doi: 10.1111/j.1349-7006.2009.01440.x. Epub 2009 Nov 16. Cancer Sci. 2010. PMID: 20028384 Free PMC article.

9

Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment.

Minami Y, Kajiguchi T, Abe A, Ohno T, Kiyoi H, Naoe T. Minami Y, et al. Int J Hematol. 2010 Nov;92(4):664-6. doi: 10.1007/s12185-010-0706-6. Epub 2010 Oct 22. Int J Hematol. 2010. PMID: 20963643

10

PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML.

Kurahashi S, Hayakawa F, Miyata Y, Yasuda T, Minami Y, Tsuzuki S, Abe A, Naoe T. Kurahashi S, et al. Among authors: minami y. Oncogene. 2011 Apr 14;30(15):1822-30. doi: 10.1038/onc.2010.554. Epub 2011 Jan 10. Oncogene. 2011. PMID: 21217775

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,583 results

Search Page

Filters